7:30am Registration, Morning Coffee
8:15 Chairperson and Opening Remarks: Nimble, Flexible, Engaged - Descriptors for a Dynamic Function, Poised to Address Rapidly Changing Needs
Joan A. Lasota, Ph.D., Senior Direcotr, Alliance Management, Merck & Co., Inc.
8:45 The State of Pharmaceutical Deal Making - What the Numbers Say
Tibor Papp, M.D., Ph.D., M.B.A., Head, Corporate Advisory, PharmaVentures, Ltd.
Pharmaceutical deal making has not escaped the economic turmoil. Changing attitudes of pharma executives and investors have often shown a negative impact on deal dynamics. Do deal makers capitalize on the special opportunities presented now? What is going to be the winning strategies in the new deal making landscape? This talk will present current statistics and insight in deal valuations and structures. Several cases of creative deal making will be shared.
SHARED 'LEARNINGS' FROM DIFFERENT TYPES OF ALLIANCES
9:15 New Frontiers in Biomarker and Drug Development - Matching Big Pharma and Biotech
Jens Thiedemann, Director, Alliance Management Oncology, Bayer Healthcare Pharmaceuticals
Bayer Oncology has a broad range of development and commercialization alliances with biotech companies. Through our experiences, we have learned how to best manage our partner collaborations that have diverse goals, strategies, and needs. A case study will be presented that showcases the best practices, pitfalls, and approaches of day-to-day challenges in alliances of unequal partners.
9:45 Co-development of Novel Therapeutic Products in China to Speed up Development of Compounds on the Back Burner – Matching Biotech and Big Pharma
Ying Luo, Ph.D., CEO, Shanghai Genomics
In light of today’s economy, biotech/pharma industry is still facing a dilemma of increasing demand of pipeline products and continuing financial restraint. Biotech companies in the West possess strong capability to invent new compound leads while biotech companies in China are strong in cost-efficient clinical development. Since 2008, Shanghai Genomics, leveraging its experience in China, has been focusing on filling its future pipeline via partnerships with Western biotechs. A case study will be presented that shows our partnership model and shared learnings.
10:15 Coffee Break, Exhibit Viewing
& One-to-One Meetings
10:45 Companion Diagnostics, Personalized Medicine and Beyond – Matching Pharmaceutical and Diagnostic
Moderator: Mark Trusheim, Executive in Residence & Visiting Scientist at MIT; former Special Government Employee, Office of the Commissioner, FDA
Cecilia Schott, Pharm.D., MBA, Business Development Director, Personalized Healthcare, Strategic Planning & Business Development, AstraZeneca
Cynthia Gawron-Burke, Ph.D., External Scientific Affairs, Merck Research Laboratories
Katherine Call, Ph.D., Senior Director, Research Strategy and External Innovation, Sanofi-Aventis
This series will feature 10 minute briefings by each speaker followed by an in-depth panel discussion for 30 minutes. Panelists will discuss partnership and the interface between pharmaceutical to diagnostic collaboration, focusing on the development and launch of a companion diagnostic from the early stages of biomarkers discovery through clinical validation of a predictive diagnostic test. The needs of a larger pharmaceutical partner will be highlighted along with feedback to potential diagnostic company partners.
11:45 Case Study: Building an Oncology Business at Genzyme through Internal Research and Transactions
Clare Fisher, Senior Director, Business Development, Oncology, Genzyme Corporation
Building on its history in orphan diseases, Genzyme is now building a commercial presence in oncology. The discussion will review how Genzyme has expanded its orphan disease focus to the broader—but still orphan-like—oncology market using both internal research as well as transactions.
12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own
1:30 Diagnostic Example
Making Personalized Medicine a Reality: Lessons Learned
Michael L. Penn Jr., M.D., Ph.D., Senior Manager, Business Development, Genentech, Inc.
Realizing the full promise of Personalized Medicine through patient-tailored diagnostics is the next major evolution of our healthcare system. There are many challenges to overcome when aligning the interests of drug makers with diagnostics companies. Building on the panel “Matching Pharmaceutical and Diagnostic”, this talk will highlight relevant themes in Personalized Medicine dealmaking from the perspective of a large biotech company. Lessons learned from past experiences will be shared, as well as an outlook on the future of personalized diagnostics.
Sponsored by
.jpg?n=1830 "Qiagen")
2:00 CDx Programs: When the Rubber Hits the Road
Peter Collins, Vice President, Pharma Business Development, QIAGEN
We are entering a new era of innovative and sustainable healthcare for patients. An integral part of the success of personalized medicine lies in companion diagnostics - the effective partnering of pharmaceutical companies with diagnostic providers. This presentation looks at QIAGEN’s (formerly DxS Ltd) past experiences and future aims in companion diagnostic development, with case studies including the creation of the first companion diagnostic for Amgen’s colorectal cancer drug Vectibix® based on mutations in the K-RAS oncogene, and the companion diagnostic for AstraZeneca’s lung cancer therapy IRESSA® using DxS’ TheraScreen® EGFR29 Mutation Kit. QIAGEN have used their experience and leadership in the field to produce a CDx program supporting the process from inception through to regulatory approval and launch.
Sponsored by
2:30 Matching Service Sponsored by Organization with Drug/Device and Drug/Diagnostic Example
Strange Bedfellows – Managing Technology Partners Successfully
Rob Neufelder, Director, Regional Operations, Integrated Project Management Company, Inc.
Healthcare reform will drive the need to provide greater clinical value in the treatment of patients, driving innovation in the life sciences industry. The area of convergent technologies is ripe for explosive growth. Drug/device and drug/diagnostic combinations, spurred by advances in personalized medicine, not only offer clinical benefits but enable life sciences companies to expand their product lines and extend their life cycles. Case studies will be presented to demonstrate how companies can successfully co-develop new combination products.
3:00 KEYNOTE PRESENTATION
A Roadmap to Improving Partnering Capability
Brenda L. Reis, Ph.D., Vice President, Project Management & Alliance Management, Wyeth Legacy
Partnering to achieve a myriad of objectives has become a critical component for business success. Yet many organizations have neither the processes nor the culture to optimally support collaborative, co-development initiatives. This talk provides a case-study for assessing partnering capability to identify obstacles that hinder effective partner collaboration. Results were used to drive improvements in alliance management practices and partner-satisfaction overall. The 4-year evolution of building alliance management capability at Wyeth will be discussed.
3:30 Refreshment Break, Exhibit Viewing & One-to-One Meetings
4:00 Interactive Discussion Groups & Report Outs
Concurrent roundtables to discuss some of the more broad yet poignant questions facing the industry. Each roundtable will be limited to twelve (12) participants and a facilitator.
Overall Moderator: Stu Kliman, J.D., Head, Pharmaceuticals Practice Area, Vantage Partners
Topic 1: How Does Alliance Management Help Companies Save Money?
Moderator: Tina Sampalis, M.D., Ph.D., President, Acasti Pharma, Inc.
Topic 2: Just Do It! Survival Techniques for Combination Product Alliances
Moderator: Dorene Lynch, Business Development Executive, Life Sciences, Integrated Project Management, Inc.
Topic 3: Business Models for Personalized Diagnostics
Moderator: Mark Trusheim, Executive in Residence & Visiting Scientist at MIT; former Special Government Employee, Office of the Commissioner, FDA
Topic 4: Creating an Alliance Supporting Culture - Ensuring Effective Behaviors Across the Organization
Moderator: Renee Jansen, Senior Consultant, Vantage Partners
Topic 5: Overcoming Challenges in Drug - Diagnostic Co-Development
Peter Collins, Vice President, Pharma Business Development, Qiagen
5:30 Networking Cocktail Reception
*Separate registration required